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Summary.-Fifteen patients undergoing surgery for Stage IIb malignant melanoma
were randomly allocated either to a group who received a vaccine of BCG mixed with
irradiated autologous melanoma cells, or a control group who received no further
treatment. All patients were monitored sequentially for immunological competence
and tumour-directed immunity, using a wide range of techniques, and the results
were compared retrospectively with their clinical course.
Three months after surgery, there was a trend towards inhibition of PHA-induced
lymphocyte transformation by autologous serum in patients who developed recurrent
tumour within 12 months after treatment. Serum from patients who remained
tumour-free for 12 months did not inhibit stimulation of autologous lymphocytes by
PHA. Apart from this test, no other immunological parameters correlated either with
clinical course or with the type of treatment received.
SEVERAL trials of immunotherapy in
patients with malignant melanoma using
bacterial adjuvants are currently in pro-
gress or have been reported (Carter, 1976;
Gutterman, 1977; Morton et al., 1976). In
some of these trials, attempts have been
made to monitor the immune status of
patients with regard to tumour-directed
immunity or general immunocompetence.
In most reports only a limited number of
different parameters have been measured.
We have recently published clinical
results of a controlled trial of active
immunotherapy in Stage Ilb melanoma,
using a vaccine of irradiated autologous
melanoma cells mixed with BCG (Mclll-
murray et al., 1977). Patients in the trial
were systematically monitored throughout
for levels of immunocompetence and evi-
dence of tumour immunity, using a wide
range of techniques, in order to identify
changes which could be correlated with
their clinical course, the primary objective
being to determine ways of identifying
patients who would benefit from immuno-
therapy. Theskinresponse ofthesepatients
to the recall antigens PPD and Varidase
has been reported (Mclllmurray et al.,
1977), and the following reports their
immune responses as measured by various
in vitro tests.
MATERIALS AND METHODS
Patients. Fifteen patients with malignant
melanoma were treated surgically forlocalized
recurrent tumour following an original opera-
tion. TheywAere judged to be tumour-free after
thorough clinical examination and after
isotope scans of liver, bone and brain, and
radiographs of chest and skeleton were
shown to be normal. They were then allocated
at random to either a treatment group (8
patients) which received a vaccine post-
operatively, or a control group (7 patients)
without further treatment. The vaccine con-
sisted of a mixture of live BCG (Glaxo,
3x 107 organisms) and 5x 107 autologous
irradiated tumour cells, and wtas given intra-
dermally on the 14th postoperative day as
described previously (Mclllmurray et al.,
1977). No additional treatment was given
to the patients in either group during the
period of study. Comparison of control and
vaccinated patients showed that they w%ere
broadly comparable in age, site of primaryM. J. EMBLETON ET AL.
tumour and extent of disease. Patients in
both groups were monitored 2 weeks post-
operatively and at intervals of 1, 2, 3, 6 and
12 months thereafter, during which time some
ofthem developed further tumour recurrence.
Cell-mediated cytotoxicity tests.-Cell-media-
ted cytotoxicity was measured against a
long-term melanoma cell line, NKI-4, using a
previously described microcytotoxicity test
(Embleton et al., 1976). Target cells were
plated in Cooke M29 ART plates at 200 per
well, and after attachment 5 x 104 effector
cells from patients or normal donors were
added to 8 replicate wells. These effector cells
were prepared from heparinized venous blood
by centrifugation on Ficoll/Triosil. Different
normal donors were used on separate occa-
sions. After 2 days' incubation at 37°C the
surviving target cells were stained and
counted. Percentage cytotoxicity by melano-
ma patients' effector cells was calculated by
comparison with effector cells from normal
donors and with target-cell wells treated with
culture medium alone.
Leucocyte Migration inhibition.-A 10,000 g
supernatant extract was prepared from a
homogenate of pooled melanoma tissue in
phosphate-buffered saline (PBS, pH 7.2) and
was stored in the vapour phase of a liquid N2
bank. Leucocytes were prepared by sedimen-
tation of heparinized blood for 30 min with
2 ml 3% gelatin per 20 ml blood. The leuco-
cyte-rich supernatant was collected and the
cells washed twice, and 107 cells were
incubated in 0*2 ml of PBS supplemented
with melanoma extract at concentrations of
10, 100 and 500 ,ug. After 2 h incubation
,2-5 x 106 cells were introduced into tripli-
cate 50 ,ul glass capillary tubes. The ends
were sealed and the tubes centrifuged to
produce a cell button. The tubes were cut at
the cell/liquid interface and the stubs with
the cell buttons were mounted in plastic
plates (Sterilin) in Eagle's MEM plus 10%
foetal calf serum. The leucocytes were allowed
to migrate at 37°C for 18 h and the areas of
migration were measured by planimetry. A
migration index was calculated as:
Migration area after antigen treatment
Migration area after PBS treatment
Complement-dependent cytotoxicity.-NKI-4
melanoma cells (5 x 104 in 100 ,A MEM) were
incubated with 100 ,ultest serum orAB control
serum for 20 min at 37TC. Rabbit serum
(300 pl 1/3 dilution in MEM) was added for a
further 60 min incubation. Aliquots of 10 [LI
were plated in 6 wells of a Cooke microtitra-
tion plate and incubated 18 h at 37°C.
Surviving cells were stained and counted,
and cytotoxicity was calculated by compari-
son with the AB control serum.
Immunofluorescence.-Slides were pre-
pared with 10 separate spots of 104 NKI-4
cells. They were air-dried and fixed with
acetone at -20°C. A drop of test or AB
control serum diluted 1/5 was placed on a
patch of fixed cells and incubated for 20 min
at room temperature in a humidified cham-
ber. The slide was washed x 3 and a drop of
1/40 dilution FITC-conjugated sheep anti-
human Ig (Burroughs Wellcome) was added.
After 20 min the slide was again washed x 3
and the cells were flooded with PBS :glycerol
(1: 1). The cells were examined under incident
blue-light fluorescence and the percentage of
cells showing cytoplasmic fluorescence was
scored.
Viable cells in suspension were used in a
membrane fluorescence test as previously
described (Baldwin et al., 1971). Aliquots of
5 x 105 NKI-4 cells were incubated with 50 ,ul
test or AB control serum for 20 min at room
temperature. After 3 washes the cells were
incubated with 50 pi1 1/20 FITC-conjugated
sheep anti-human Ig for 20 min. The cells
were again washed x 3 and suspended in
100 ,ul PBS:glycerol (1: 1). They were exam-
ined under transmitted UV illumination and
a fluorescence index was calculated as:
% cells unstained in control-
% cells unstained in test serum
% cells unstained in control
Lymphocyte-stimulation tests.-Leucocytes
were prepared from defibrinated venous blood
by plasmagel sedimentation of red cells.
Aliquots of 2 x 105 leucocytes were set up in
culture in microtest plates using RPMI 1640
medium with a bicarbonate/CO2 buffer
system. The individual culture volumes of
0-22 ml included 10% autologous or AB
serum. The following mitogens were added
(or saline as control) in a further 0-02 ml:
purified phytohaemagglutinin (Burroughs
Wellcome; PHA) at 1.0 ,ug/ml and 0 5 jug/ml;
concanavalin A (Miles: Con A) at 50 Hg/ml,
and pokeweed mitogen (Gibco; PWM) at
1/100 dilution. All concentrations given are
the final concentration of the mitogen in
the cultures.
3H-thymidine (sp. act. 200 mCi/mmol) in
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0-02 ml was added 24 h before harvesting at
,90 h of culture. This level of specific
activity was selected to give the least error
due to the inherently variable cold thymidine
pool (Knight, S.C., personal communication).
This comparatively low level oflabelling gave
counts of 20-30 ct/min in control wells (i.e.
with saline instead ofmitogen) with a normal
range of responsiveness to the standard
mitogens as indicated in Table I. Stimulation
was expressed as the increment in ct/min
over that found in the saline controls.
Serum immunoglobulins and complement.-
IgA, IgG, IgM, C3 and C4 were measured
by radial immunodiffusion (Mancini et al.,
1965) and IgE was measured by radio-
immunoassay. CH50 was determined by the
method of Mayer (1973).
Othermeasurements.-Totalleucocytes were
counted by Coulter counter, and total
lymphocytes were counted microscopically.
Serum glutamate-pyruvate transaminase
(SGPT) and alkaline phosphate (using DNP
phosphate substrate) were assayed by stand-
ard methods. Erythrocyte sedimentation
rate (ESR) and haemoglobin were also
measured.
Statistics.-Comparisons between different
groups ofpatients were statistically evaluated
by the Mann-Witney U test for non-para-
metric data.
RESULTS
The results are grouped to enable 2
comparisons to be made. Firstly the
vaccinated patients are compared with the
control patients, and the mean 2-week
postoperative values (4i s.e. mean) for the
various parameters are shown in Table I.
The means orrangesfornormalindividuals
are included for comparison. Tests for
tumour-directed immunity showed similar
activities in both groups of melanoma
patients. Cell-mediated cytotoxicity was
TABLE L.-Pretreatment Measurements ofImmune Function in Vaccinated and
Non-vaccinated Control Patients
Immunological tests
Cell-mediated cytotoxicity (cf. normal donor)* (%)
Cell-mediated cytotoxicity (cf. medium) (%)
Leucocyte migration index
Complement-dependent cytotoxicity (%)
Fixed cell immunofluorescence (%)
Membrane fluorescence index
PHA (1 ,ug/ml) AB serum (ct/min)
PHA (1 ,ug/ml) autologous serum (ct/min)
PHA (0-5 ,ug/ml) AB serum (ct/min)
PHA (05 ,ug/ml) autologous serum (ct/min)
PWM AB serum (ct/min)
PWM autologous serum (ct/min)
Con A AB serum (ct/min)
Con A autologous serum (ct/min)
C'3 (mg/100 ml)
C'4 (mg/100 ml)
C'Ho5 (titre)
IgG (mg/100 ml)
IgA (mg/100 ml)
IgM (mg/100 ml)
IgE (units/ml)
IgD (mg/ml)
Haemoglobin (g/100 ml)
Total leucocytes (x 109/1)
Lymphocytes (per mm3)
Alkaline phosphatase (iu/ml)
SGPT (iu/ml)
ESR
All
vaccinated
patients
-2±9
31±8t
0 74±0 08
33±10
39±5
001±0*01
387±84
281±115
129±43
58±16
1285±417
1292±417
631 ±253
989±560
163±10
47±3
261±19
945± 76
345± 68
73±7
49±10
15+6t
14-4±0 -5
7 -6±0 -4
2222± 148
66±7
14-0±2 9
22 -4±5 - 3
All
control
patients
-5±11
6±5t
0-79±0-10
59± 13
27± 17
0 02±0-01
682±33
290± 111
521±357
117±52
712 ± 186
591±158
588±294
361±58
155± 14
54±7
276± 17
952± 182
276± 27
119±44
87±25
77 +24t
13 -8±0 -2
7 00 06
2293±539
63±8
11 2±1 9
14-2±4- 8
Normal
values
12±7
0 94±0 11
49-± 12
30 10
0*01±0*01
1200-3800
1000-3000
300-2500
250-1500
300-2200
500-2000
1400-3500
1400-3500
>100
>15
>200
500-1600
125-425
50-175
<200
13-16 -5
4-11
1500-3500
22-92
2-19
<-11
* Cell-mediated cytotoxicity was calculated with reference to cytotoxicity by normal donor mononuclear
cells (cf. normal donor) and also by reference to target cell survival in culture medium alone (cf. medium).
t Cell-mediated cytotoxicity (cf. medium) and IgD measurements showed significant differences between
vaccinated and control patients (P<0.05). No other differences are statistically significant.
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slightly higher in the group subsequently
given vaccine than in controls or normal
subjects (P < 0.05) and both melanoma
groups showed slightly inhibited leucocyte
migration following treatment with mela-
noma extract, compared with normal
people. However, these differences were
not very great, and none of the serological
tests showed any significant difference
between either melanoma group or normal
donors. Lymphocyte stimulation by PHA
was lower in the melanoma patients than
in normal individuals, but still well above
background levels; stimulation in AB
serum was lower in patients who were
subsequently vaccinated than in those
who were not. In both groups of patients,
the stimulation was less in autologous
serum than in AB serum. With the excep-
tion of the raised ESR, the mean values
for the various haematological and sero-
logical parameters were within the normal
range. Apart from cell-mediated cytotoxi-
city, the onlysignificantdifferencebetween
vaccinated and control patients was the
lower IgD level in the vaccinated group
(P < 0.05).
Secondly, patients who remained
tumour-free for 12 months were compared
with those who developed recurrent tum-
our within 12 months ofsurgery. The mean
2-week postoperative values (+ s.e. mean)
for these patients are shown in Table II.
Again, the results of tests for tumour-
directed immunity showed both groups to
be similar and no differences emerged
which could be associated with varying
prognosis. Serum Ig, complement and
enzyme levels, and white-cell counts were
also similar in both groups. There were
differences inthe effectofautologousserum
on lymphocyte responses to PHA between
the 2 groups. Thus, autologous serum in-
hibited PHA responsiveness at a PHA
concentration of 1 /tg/ml but this effect
was more marked in patients who later
TABLE II.-Pretreatment Measurements of Immune Function in Patients Remaining
Tumour-freefor 12 monthsandPatientsDevelopingRecurrentTumourwithin 12 months
Immunological tests
Cell-mediated cytotoxicity (cf. normal donor) (%)
Cell-mediated cytotoxicity (cf. medium) (%)
I,eucocyte migration index
Complement-dependent cytotoxicity (%)
Fixed cell immunofluorescence (%)
Membrane fluorescence index
PHA (1 ,ug/ml( AB serum (ct/min)
PHA (1 ,tg/ml) autologous serum (ct/min)
PHfA (0-5 ,tg/ml) AB serum (ct/min)
PHA (0-5 ,ug/ml) autologous serum (ct/min)
PWM AB serum (ct/min)
PWM autologous serum (ct/min)
Con A AB serum (ct/min)
Con A autologous serum (ct/min)
C'3 (mg/100 ml)
C'4 (mg/100 ml)
C'H50 (titre)
IgG (mg/100 ml)
IgA (mg/100 ml)
IgM (mg/100 ml)
IgE units/ml
IgD (mg/ml)
Haemoglobin (g/100 ml)
Total leucocytes (x 109/1)
Lymphocytes (per mm3)
Alkaline phosphatase (iu/ml)
SGPT (iu/ml)
ESR
All tumour-free
patients
4±9
21±5
0 77±0-09
32±10
51±16
0-02±0-01
482± 72
432± 128
235±52
120±44
1112±266
1036± 294
469± 80
563i111
164± 7
53±4
257± 10
1030± 106
3094±51
44±33
92±26
55±22
13 -6±0 - 4
7-3±0 5
2389±430
61±6
14-9±2 - 7
23 -66 -62
All tumour-recurrent
patients
-7±12
24± 11
0 80±0-08
56±13
24±15
0 02±0 01
5424 297
179±46
385±317
61±18
852±393
834± 380
797± 329
840±574
150±14
47±5
275±20
897±129
325± 61
89+14
56±9
22± 8
14-7±0-5
7 4±0*6
2119+ 172
68±8
10-9±2-5
12-1±9-5
No differences between measurements on tumour-free and tumour-recurrent patients were statistically
significant.
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developed recurrent disease than in those
who remained tumour-free during the 12-
month period. The same effect was not
observed with the mitogens PWM and
Con A. The ESR was higher in tumour-
free individuals than in patients develop-
ing recurrent tumours.
Following surgery, most ofthe measure-
ments fluctuated but showed no consistent
changes, either in vaccinated or control
patients, or in patients from either grouip
who developed tumour within 12 months.
This made it necessary to compare groups
of patients ratlher than individuals. Some
patients developed early recurrences (Mc-
Ilimurray et al., 1977) and were thereafter
exclutded from the study; complete data
for- all patients were therefore obtained
only up to 3 months after treatment. Some
changes appeared in the cell-mediated
cytotoxicity and lymphocyte-stimulation
tests, and the values for these tests at 3
months are shown in Table 111. Cell-
meediate(1 cytotoxicity compared with
medium controls increased from the low
initial level of 6 to 26% at 3 months in
control patients. Cytotoxicity in tumour-
free patients was similarly raised at 3
months. In contrast, the value in vac-
cinated patients developing recurrent tum-
ours fell from an initial 410% to 80% at 3
months, although tumour-recurrent con-
trol patients showed similar cytotoxicity
to tumour-free patients at 3 months.
Stimulation by Con A showed an increase
in most groups at 3 months over initial
values, but PHA and PWM showed no
major change in the presence ofAB serum.
However, differences were observed in
PHA cultures with autologous serum. Any
initial tendency towards inhibition of
PHA stimulation by autologous serum in
patients who remained tumour-free had
disappeared by 3 months. In contrast,
PHA stimulation was clearly inhibited at
3 monthls in all patients who developed
recurrent tumour. No consistent difference
emerged between vaccinated and control
patients, so that inhibition of PHA stimu-
lation by autologous serum at 3 months
was correlated with the growtlh of ttumouir
rather than vaccination status. Measure-
ments on patients who remained evaluable
after 3 months showed no further changes
which could be correlated with clinical
course.
DISCUSSION
Several reports have been published
concerning monitoring of immune re-
sponses in malignant-melanoma patients
in an attempt to find factors which cor-
relate with their clinical course. Most
studies h-ave concentrated on the detection
of tumour-directed immunity, especially
the cell-mediated response, using a variety
of techniques such as cytotoxicity tests
(Reithmuller et al., 1975; Hellstr6m et al.,
1973; Heppner et al., 1973; Bodurtha et al.,
1976), leucocyte migration inhibition (Mc-
Coy et al., 1975; Lieberman et al., 1975) or
lymphocyte stimulation by melanoma ex-
tracts (Spitler et al., 1976; Lieberman et
al., 1975). In this report, a wide range of
non-specific and tumour-directed immunie
phenomena has been investigated on the
same patients repeatedly, so that a retro-
spective comparison could be made on,the
results of these and the clinical outcome.
The clinical results ofthis study have been
published (Mclllmurray et al., 1977). It
was soon apparent that a number of vac-
cinated patients relapsed more quickly
than controls, so the trial was stopped at
an early stage. Consequently the numbers
in both control and vaccinated groups
were small and, together with the vari-
ability experienced, this meant that most
of the differences observed were not
statistically significant. In spite of this,
however, certain trends were observed and
some conclusions can be drawn from the
study.
Attempts to find correlations between
prognosis and tumour-directed immunity
were essentially negative. No evidence of
increased serological activity could be
detected in melanoma patients compared
with normal donors, and none of the
patient groups (control, vaccinated, tum-
our-free or tumour-recurrent) was signifi-
cantly different from another. Also, little
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difference was observed between any of
the patient groups with regard to tests for
cell-mediated immunity. Leucocyte migra-
tion inhibition in response to melanoma
extract was slightly greater in melanoma
patients than in control donors, but not
convincingly so, and cell-mediated micro-
cytotoxicity was low when compared with
that of normal donors rather than with
medium controls. Other workers studying
cell-mediated immunity (CMI) to mela-
noma have claimed correlations between
increased CMI and good prognosis or BCG
treatment (Reithmuller et al., 1975; Spit-
ler et al., 1976; Lieberman et al., 1975;
Bodurtha et al., 1976). In some cases,
patients with recurrent tumour have been
shown to have increased serum blocking
or inhibitory factors, interfering with
CMI, than tumour-free patients (Hell-
strom et al., 1973; Heppner et al., 1973;
Currie and McElwain, 1975). The reasons
for inadequacy of the tests for tumour
immunity in the present study could
possibly stem from the use of a single
target-cell line or tumour extract with
allogeneic patients. Better results might
have been obtained with a panel of cell
lines or extracts, or with autochthonous
tumour cells, although both approaches
are still fraught with problems, owing to
limitations of the techniques used (re-
viewed by Baldwin and Embleton, 1977).
Measurements of serum components
(immunoglobulins and complement) and
total leucocyte or lymphocyte counts,
rather surprisingly, also failed to reveal
differences between melanoma patients
and normal donors. In view of the de-
creased immunocompetence often seen in
patients with advanced cancer, differences
could have been expected in the tumour-
recurrent group. There was a tendency
towards lower initial response to PPD
skin testing in patients who subsequently
developed recurrences within 12 months
(Mclllmurray et al., 1977) but this dif-
ference was not paralleled by in vitro
measurements. However, some differences
were seen in the blastogenic response of
the patient to phytohaemagglutinin
(PHA). Overall, the PHA response of the
melanoma patients was lower than that
normally seen in healthy donors (Table I).
Over and above this, a suppressive effect
was often noted in the presence of auto-
logous serum. In this case, PHA stimula-
tion was lower in the presence of auto-
logous serum than in homologous AB
serum. This effect was not consistent
before treatment but, at 3 months after
treatment, there was a clear trend towards
autologous-serum inhibition of lympho-
cyte transformation in patients who
developedrecurrent tumour, whereasthose
who remained tumour-free were not sup-
pressed by autologous serum. By 3 months
there was clinical evidence of relapse in
some patients (Mclllmurray et al., 1977) so
in this sense the test was not prognostic,
but if its validity could be confirmed in a
larger trial and the inhibitory factor
characterized, it might be ofvalue in over-
all assessment of the patient's clinical
course. Similar inhibition ofPHA lympho-
cyte stimulation by autologous serum has
been reported by Amlot and Unger (1976)
in patients with Hodgkins's disease, and
in this case the inhibitory effect resided in
a PHA-binding macromolecular serum
fraction. The relationship between the
serum inhibitory factor responsible for
suppression of PHA stimulation and
blocking factors which interfere with
tumour-directed CMI (Hellstrom et al.,
1973; Heppner et al., 1973) is not known,
but this problem may be worthy offurther
study.
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